Mont-Saint-Guibert, Belgium, –Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it intends to appoint Hanspeter Spek as a Non- Executive Director. The appointment is expected to be formalized at C3BS’ next general assembly on May 5th 2014.
Hanspeter started his career at Pfizer where, over more than ten years and after a thorough comprehensive training in commercial general management, he held positions of increasing responsibility. He then joined Sanofi as Marketing Director and rose through the organization to become the Executive Vice President International in 2000. When Sanofi and Aventis merged in 2004, he took on the responsibility of Executive Vice President Operations. In 2009, he was nominated President Global Operations. He retired from Sanofi in mid-2013. He has since joined Advent as a Senior Advisor for Healthcare. He continues to serve on the Board of Sanofi, Germany, as Chairman.
Dr Christian Homsy, CEO of Cardio3 BioSciences comments: “We are extremely proud that an executive of the caliber of Hanspeter has decided to join the Board of C3BS, reflecting our leadership in our field. His extensive experience in building partnerships and leading operations, marketing and sales will be invaluable in best preparing our company to commercialize C-Cure®. As a member of the Executive Committee at Sanofi, Hanspeter has been a key participant in numerous partnerships, acquisitions and licensing deals, and, as such, he will further enhance our capability to pursue business development opportunities and allow us to benefit from his perspective as a large healthcare industry executive.”
Commenting on his new role, Hanspeter Spek said: “I am honored to have the opportunity to contribute to the future development of C3BS. With the CHART-1 Phase III program running in Europe and approval to commence CHART-2 from the US FDA, the Company is positioned at the forefront of regenerative medicine. Heart disease remains an area of substantial unmet medical need and I look forward to bringing my experience of development, launch preparation and worldwide commercialization to the Board and to working with the team to deliver on C-Cure’s potential.”
